AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00772200 — intervention group
Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Complete COG Standard Neuropsychological and Behavioral Battery
Study NCT00772200 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01412216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil (Omega-3 Fatty Acids)
Description: fish oil-4.4gm/day x 5 days
Study NCT01412216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil (Omega-3 Fatty Acids)
Study NCT03403738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bounce Back Now
Description: web/smartphone-based intervention for disaster victims
Study NCT03527030 — intervention group
Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in the General Population
Description: Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
Study NCT03403738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: enhanced usual care
Description: enhanced usual care with list of resources
Study NCT03527030 — intervention group
Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in IQOS Users
Description: Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
Study NCT03561961 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Hypo-fractionation
Description: 66-68Gy in 25#
Study NCT03561961 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Extreme Hypo-fractionation
Description: 35-36.25 Gy in 5#
Study NCT02511990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg, single dose IV administration of 10-1074
Description: 3 mg/kg, single dose IV administration of 10-1074
Study NCT03148938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Assessment on mobile
Description: The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test
Study NCT03148938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Assessment on mobile
Description: The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test
Study NCT02511990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, single dose IV administration of 10-1074
Description: 10 mg/kg, single dose IV administration of 10-1074
Study NCT02511990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 10-1074
Description: 30 mg/kg, single dose IV administration of 10-1074
Study NCT04473846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK general anesthesia
Description: Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
Study NCT04473846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFK combination
Description: Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
Study NCT02297048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium depletion
Description: Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
Study NCT02297048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium depletion
Description: Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
Study NCT02682771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure
Description: The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
Study NCT02682771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerBreathe
Description: Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
Study NCT02682771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Respiratory Physiotherapy (CRP)
Description: CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
Study NCT02682771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Respiratory Physiotherapy (CRP)
Description: CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
Study NCT01356927 — intervention group
Intervention type: DRUG
Intervention: DMPA
Description: DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
Study NCT01356927 — intervention group
Intervention type: DRUG
Intervention: Etonogestrel implant
Description: Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
Study NCT01033851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: 8 week course
Study NCT01033851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Education
Description: 8 week course
Study NCT02795026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
Study NCT02795026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trigger point dry needling
Description: Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
Study NCT02991313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial Ablation Procedure
Study NCT04080999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: r-TMS
Description: The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
Study NCT04080999 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
Study NCT03922139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA Injection
Description: Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle.
Study NCT03343639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Serlopitant Tablets
Description: Serlopitant Tablets
Study NCT03343639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablets
Description: Placebo Tablets
Study NCT03561987 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
Study NCT03240120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Pradaxa 150 mg hard capsules
Study NCT03240120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
Study NCT03912064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an antibody that acts against CTLA-4
Study NCT03912064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD25hi Treg depleted DLI
Description: Donor lymphocyte product
Study NCT01498601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced oral care protocol
Description: * Changing mouth suction equipment every 24 hours~* Mouth assessment every 2-4 hours~* Cleansing mouth with toothbrush every 12 hours~* Cleansing oral mucosa with oral rinse solution every 2-4 hours~* Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~* Suction mouth and throat as needed~* Head of the bed elevated to a minimum of 30° during oral care
Study NCT00003700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC > 5,000 uL after nadir: 7 day minimum for Courses I \& IV
Study NCT02915809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110B vaccine
Description: 0.5mL, Intramuscular
Study NCT05108714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)
Description: Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
Study NCT02915809 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Quadrivalent Inj. vaccine
Description: 0.5mL, Intramuscular
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: 6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I \& IV
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2000 mg/sq m IV infusion over 3 hrs Days 1,2, \& 3: Courses II \& V
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: 80mg/sq m (pts\<60y/o)OR 60mg/sq m (pts =/>60y/o) IV infusion over 5-10 min Days 1,2,\& 3: Courses I \& IV
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60mg/sq m/d PO every day Course VII
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/sq m/day PO Days 1-21 (pts\<60y/o) OR Days 1-7 (pts >/= 60y/o) Courses I \& IV and Days 1-5 of ea 4 cycle in Course VII
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 2 mg total IV infusion Days 1,8,15,\& 22 Courses I \& IV and Days 1, 8, \& 15 Courses III \& VI, and Day 1 of ea 4 wk cycle in Course VII
Study NCT05108714 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device
Description: Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.
Study NCT05108714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)
Description: Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
Study NCT02639962 — intervention group
Intervention type: RADIATION
Intervention: Cardiac CT
Description: Cardiac CT before the CAG, and follow up after 2 month and 12 month
Study NCT05108714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous cannulation after without prior interventions
Description: insertion of 18G catheter in a cubital vein without prior interventions.
Study NCT03954132 — intervention group
Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
Study NCT03954132 — intervention group
Intervention type: DRUG
Intervention: Triple-Therapy (LAMA/LABA/ICS)
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
Study NCT00052780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: Given IV
Study NCT00052780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT00052780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC or IV
Study NCT00052780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00052780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01617525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Feeding Dietary Intervention
Description: All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
Study NCT01617525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Feeding Dietary Intervention
Description: All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
Study NCT02586064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy for PTSD
Description: Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
Study NCT02586064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
Study NCT03773367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Study NCT03773367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Study NCT03773367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Study NCT01469234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine
Description: loratadine, one 10 mg tablet, orally
Study NCT01469234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: fexofenadine, one 180 mg tablet, orally
Study NCT01469234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to loratadine
Description: one tablet, orally
Study NCT01469234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to loratadine
Description: one tablet, orally
Study NCT01469234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to fexofenadine
Description: one tablet, orally
Study NCT01469234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to fexofenadine
Description: one tablet, orally
Study NCT06742151 — intervention group
Intervention type: PROCEDURE
Intervention: implant can be placed or not
Description: the possibility of receiving dental implants
Study NCT00423514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00423514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Study NCT00423514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00423514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00423514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT00423514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT00423514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00423514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00423514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01836965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Intervention
Description: Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
Study NCT02674776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuZhen Capsule
Description: Patients should take 4 tablet once and 3 times per day for 3 days.